Alimera Sciences, Inc. (NASDAQ:ALIM) insider Richard S. Eiswirth, Jr. sold 13,410 shares of the stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $1.20, for a total value of $16,092.00. Following the transaction, the insider now owns 84,779 shares of the company’s stock, valued at $101,734.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) remained flat at $$1.09 during midday trading on Friday. 256,305 shares of the company were exchanged, compared to its average volume of 161,069. Alimera Sciences, Inc. has a 12 month low of $1.03 and a 12 month high of $1.72. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71.
A hedge fund recently raised its stake in Alimera Sciences stock. Stonepine Capital Management LLC grew its holdings in Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 477,226 shares of the biopharmaceutical company’s stock after buying an additional 292,399 shares during the period. Alimera Sciences accounts for about 0.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned approximately 0.69% of Alimera Sciences worth $644,000 at the end of the most recent quarter. Institutional investors and hedge funds own 41.77% of the company’s stock.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.